Fleur G. Cornelissen
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype.
Journal: Molecular cancer therapeutics
Published: December 07, 2023
Explaining Blood-Brain Barrier Permeability of Small Molecules by Integrated Analysis of Different Transport Mechanisms.
Journal: Journal of medicinal chemistry
Published: May 22, 2023
Practice variation in the conservative and surgical treatment of chronic subdural hematoma.
Journal: Clinical neurology and neurosurgery
Published: March 30, 2020
A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities.
Journal: Nature communications
Published: April 12, 2019
The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: February 16, 2019
WINDOW consortium: A path towards increased therapy efficacy against glioblastoma.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: July 17, 2018
Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.
Journal: Molecular cancer therapeutics
Published: May 24, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026